Distinctions and Parallels Among TRK InhibitorsVideo Categories: NTRK Gene Fusions
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors.
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.
Ken Schaecher, MD, Medical Director of SelectHealth, describes in his opinion how there is no payer coverage issues with patients with polycythemia vera at this time. Supported through funding from Incyte